ProfileGDS5678 / 1422819_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 82% 84% 84% 85% 85% 84% 82% 85% 84% 84% 82% 86% 85% 85% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.9195482
GSM967853U87-EV human glioblastoma xenograft - Control 26.3057184
GSM967854U87-EV human glioblastoma xenograft - Control 36.2292484
GSM967855U87-EV human glioblastoma xenograft - Control 46.527585
GSM967856U87-EV human glioblastoma xenograft - Control 56.3383685
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.0522884
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.7382182
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.2784385
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.2189484
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.2931784
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.9763782
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.5782686
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.3478285
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.2860985